ChronicleBio

Dolphin

Dolphin

Senior Member (Voting Rights)
Solve ME shared this on their social media:

Congratulations to our partner ChronicleBio on their big launch today!
—-

We’re building the world’s most advanced, AI-powered data platform for neuroimmune disorders like POTS, ME/CFS, Long COVID, and other complex chronic conditions that have been overlooked for far too long.

Millions of patients are living without answers or effective treatments—not because these conditions aren’t real or serious, but because the tools to understand them haven’t existed. We’re here to change that.

ChronicleBio brings together cutting-edge technology, precision biobanking, and patient-centered research to drive discovery where it’s needed most.

Our mission:
Generate rich, multi-omic datasets
Power AI models for real-world discovery
Unlock new diagnostics, treatments, and clinical trial opportunities

We’re honored to partner with patients, clinicians, and researchers worldwide. This is just the beginning.

https://chroniclebio.com/news/mergi...llions-living-with-complex-chronic-conditions
 
ChronicleBio is uniquely led by a founding team that unites elite tech, healthcare, and life sciences:

  • Fidji Simo (Co-founder), current CEO of Instacart and the incoming CEO of OpenAI’s applications division, brings deep expertise in consumer-scale technology, product innovation, and health systems transformation.
  • Rohit Gupta (Co-founder & CEO), a biobanking and precision medicine leader who previously oversaw centers at Stanford and UCSF, is the leading scientific and strategic force behind ChronicleBio.
  • Rishi Reddy (Co-founder & Executive Chairman), of Tarsadia Investments, brings an entrepreneurial and venture-backed perspective and a track record in health and life sciences investing.
Click to expand...
ChronicleBio’s founding vision isn’t just ambitious. It’s personal. Both Simo and Reddy have been diagnosed with at least one of the very conditions the company is focused on researching. Gupta’s family also suffers from neuroimmune disorders.
Click to expand...
ChronicleBio’s approach includes:
  • A global biobank platform collecting and connecting data on neuroimmune illnesses
  • A proprietary, AI-ready data engine designed to integrate multi-omic, clinical, and real-world evidence
  • Strategic partnerships with clinics, research consortia, and biotech sponsors looking to unlock hard-to-crack therapeutic areas
  • A decentralized clinical trial network accelerating drug development through real-world access to patients and clinicians
Click to expand...
Can’t say I fully understand what exactly they are going to do, but it seems to at least be headed by people that might be able to make it happen.
 
Posts moved from: Very Wealthy people’s charities — News, Advocacy Ideas etc.



““If you look at a condition like [ME/CFS], it is considered the most disabling disease of all diseases. When you look at the disease chart, it’s completely at the bottom, worse than cancer. The amount of funding for this condition, it’s pathetic”

Link to paywalled article on Fidji Simo
 
Last edited by a moderator:
This two quotes sum it up for me,

"In preparation for this interview, you sent me an article that you said encapsulates ChronicleBio’s approach. It talks about how some patients with long COVID were participating in a clinical trial. The drug was working well for them, but then the trial was canceled for supposedly being ineffective for the group as a whole.

Fidji Simo: Yes, so that’s really what ChronicleBio is meant to solve. We have seen a lot of clinical trials fail because the pharmaceutical companies aren’t able to identify which subset of patients [a drug] could work for. So they end up giving the drug to everyone with the same diagnosis. Let’s say it’s POTS. But there could actually be five sub-diseases within POTS, and the drug would work for one of them, but not the other four. So the clinical trial fails when it could have succeeded if we could have identified these people upfront. It seems really simple, but it hasn’t been done for these conditions."

and

"How much will it cost?

We’re making it free for the first 250 patients because we really want to make sure they are getting value out of the report. After that, it’s going to cost $400. We’re doing it at cost, meaning that’s what it costs us, and we’re charging the same for patients. The whole point for us is not to make money. It’s to collect data so we can find cures."

So ChronicleBio is off topic for this thread.
 
Felixm99 said:
The people involved have world class track records in building companies and are sick themselves.
Click to expand...

As Utsikt says, if a drug has no effect on the total cohort studied there is no legitimacy in arguing that it is missing responder subgroups. This is the standard let out that private physicians and advocacy groups use to justify off label treatments and it is holding up meaningful scientific progress no end.

Having a track record in building companies is not something i associate with biomedical science expertise, or even common sense.

I am not quite sure what they are selling for $400 but it looks distinctly like a scam - as so many companies in medicine are.
 
Jonathan Edwards said:
As Utsikt says, if a drug has no effect on the total cohort studied there is no legitimacy in arguing that it is missing responder subgroups. This is the standard let out that private physicians and advocacy groups use to justify off label treatments and it is holding up meaningful scientific progress no end.

Having a track record in building companies is not something i associate with biomedical science expertise, or even common sense.

I am not quite sure what they are selling for $400 but it looks distinctly like a scam - as so many companies in medicine are.
Click to expand...
I see you point, thanks.

The way I understand the company is not that they are set on one specific treatment. Rather they assume, rightly so I believe, that POTS and other illnesses like ME/CFS are not one disease and need to be subgrouped.
I think they are trying to do just that, beginning with POTS, collecting lots of data per person and trying to identify subgroups.
 
Felixm99 said:
Rather they assume, rightly so I believe, that POTS and other illnesses like ME/CFS are not one disease and need to be subgrouped.
Click to expand...
I think that’s probably correct, the problem is that if a treatment shows no effect at a group level. It probably doesn’t help even a small subgroup. Since even if it helped only a small amount the average score of the group would improve.

Jaybee00 said:


““If you look at a condition like [ME/CFS], it is considered the most disabling disease of all diseases. When you look at the disease chart, it’s completely at the bottom, worse than cancer. The amount of funding for this condition, it’s pathetic”

Link to paywalled article on Fidji Simo
Click to expand...

By the way Taylor Lorenz is an ally, they are very Long COVID aware and atleast 2-3 years ago when I talked to them a bit on social media were active on Long COVID twitter and the r/covidlonghaulers reddit.
 
Felixm99 said:
I see you point, thanks.

The way I understand the company is not that they are set on one specific treatment. Rather they assume, rightly so I believe, that POTS and other illnesses like ME/CFS are not one disease and need to be subgrouped.
I think they are trying to do just that, beginning with POTS, collecting lots of data per person and trying to identify subgroups.
Click to expand...
Lots of people have tried to subgroup already, and not found much.

I’m also not convinced it’s the right order of operations. Are there any examples of diseases where subgrouping has made a significant impact on our understanding of a disease before we understood the main mechanisms of the disease?
 
Utsikt said:
Are there any examples of diseases where subgrouping has made a significant impact on our understanding of a disease before we understood the main mechanisms of the disease?
Click to expand...
I believe asthma is an example. Again, the way I read the interview does not suggest that they are fixed on any one treatment.

In general, I am just very happy about any serious private company effort in this space. These people have already raised $15 mio after a year and collected more biological data than most government funded studies do in years. We can only benefit from these companies
 
Felixm99 said:
I think they are trying to do just that, beginning with POTS, collecting lots of data per person and trying to identify subgroups.
Click to expand...

But POTS is probably not a useful clinical category anyway. Subgroup that and you get big garbage in and little bits of garbage out.

And they are very emphatic about believing that patients who feel they have benefited in trials have actually benefited. The history of drug development suggests that this is unlikely - most drugs don't work but there are always people who thin they were helped. So money goes down the drain and people continue to be misled.
 
Felixm99 said:
We can only benefit from these companies
Click to expand...
I’m always slightly sceptical of companies in general, so maybe this is unfair of me. But IMO the true benefit would come from the company releasing the data so it can be independently researched. But as a private company it has little incentive to do so, since having more knowledge than rivals is a competitive advantage for companies.

I haven’t read the interview so maybe I’m wrong. But that’s my worry.
 
Are you sure it would be pointless ? In your opinion, wouldn't it reveal anything about people with orthostatic tachycardia? If I understand correctly, regarding this forum, which I genuinely love, it would be incorrect to consider POTS a valid syndrome based on its current definition ?

That said, we are all waiting for help from AI, and above all, for money...
 
neophyte32 said:
Are you sure it would be pointless ? In your opinion, wouldn't it reveal anything about people with orthostatic tachycardia?
Click to expand...

I doubt that collecting data from patients is the place to start. The place to start would be with a physiological measurement associated with symptoms and a rationale for using a drug under a specific set of circumstance.

In a sense there is a good argument for 'subsetting' but really what you want to do is to identify some particular physiological measure and treat the people who show it. But if you start with a label like POTS and canvas for information from patients online I see little chance of getting anywhere.
 
You must log in or register to reply here.
Back
Top Bottom